180 Life Sciences Corp. (NASDAQ:ATNFW) Short Interest Update

180 Life Sciences Corp. (NASDAQ:ATNFW) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 22,700 shares, a decline of 26.5% from the July 15th total of 30,900 shares. Based on an average daily volume of 205,600 shares, the short-interest ratio is currently 0.1 days.

180 Life Sciences Price Performance

Shares of ATNFW opened at $0.01 on Thursday. The firm has a fifty day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01. 180 Life Sciences has a twelve month low of $0.00 and a twelve month high of $0.03.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.